We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Ligand Pharmaceutical Inc (LGND) Com Stk Class 'B' USD0.001

Sell:$155.23 Buy:$155.81 Change: $1.61 (1.03%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $1.61 (1.03%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $1.61 (1.03%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.

Contact details

3911 Sorrento Valley Blvd Ste 110
United States
+1 (858) 5507500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.62 billion
Shares in issue:
16.71 million
United States
US dollar

Key personnel

  • Matthew Foehr
    President, Chief Operating Officer
  • John Higgins
    Chief Executive Officer, Director
  • Matthew Korenberg
    Chief Financial Officer, Executive Vice President - Finance
  • Charles Berkman
    Senior Vice President, General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.